Allurion Technologies Reports 47% Revenue Decline and $6.1 Million Net Loss in Q1 2026

Allurion Technologies, Inc. reported a significant decline in financial performance for the first quarter of 2026, with revenues totaling $2.9 million, a decrease of 47% compared to $5.6 million in the same period of 2025. The company attributed this drop primarily to reduced investment in sales and marketing as it shifts its strategy from direct-to-consumer sales to a "business to business to customer" model. Additionally, the company has been managing credit risk by limiting sales to certain distributors and accounts. The gross profit also fell sharply, down 70% to $1.2 million, largely due to increased charges for excess and obsolete inventory.

Operating expenses decreased to $5.0 million from $11.4 million year-over-year, reflecting a 56% reduction. This decline was driven by substantial cuts in sales and marketing expenses, which fell by 64% to $1.3 million, as well as a 65% reduction in research and development costs, which totaled $0.9 million. General and administrative expenses also decreased by 47% to $2.7 million, primarily due to lower legal and professional fees and reduced salaries following a restructuring initiative. Despite these reductions, the company reported a net loss of $6.1 million for the quarter, compared to a loss of $1.5 million in the prior year.

Allurion's operational metrics indicate a strategic shift following the completion of its business combination with Compute Health in August 2023. The company has been focusing on enhancing its product offerings, including the Allurion Smart Capsule, which is now FDA-approved for weight loss in adults with obesity. The company is also expanding its Allurion Virtual Care Suite, which provides remote patient monitoring tools and aims to improve patient engagement and outcomes. As of March 31, 2026, Allurion had cash and cash equivalents of $5.1 million, down from $5.4 million at the end of 2025, and it continues to face challenges in maintaining compliance with NYSE listing standards.

Looking ahead, Allurion anticipates ongoing operating losses as it invests in regulatory approvals and product development. The company has indicated a need for additional funding to support its operations, which may come from equity offerings or debt financing. The management has expressed uncertainty regarding the timing and amount of future capital raises, emphasizing the risks associated with its business model and market conditions. The company is actively working to address its internal control weaknesses and improve its financial reporting processes, which have been identified as material weaknesses in its recent filings.